BCIQ Profiles

Company Profile Report
0610 Kurome Medicxi EMB Thu 7a ET
BioCentury & Getty Images

Emerging Company Profile

With Medicxi’s backing, Kurome seeks best-in-class IRAK4 program for blood cancers

Emerging Company Profile: Kurome seeks edge in efficacy, durability for AML

Jun 10, 2021 | 11:00 AM GMT

With early clinical data emerging that suggest a combination of IRAK4 and FLT3 inhibition may be effective in treating acute myelogenous leukemia, Medicxi has thrown its

Read the full 652 word article

How to gain access

Continue reading with a
two-week free trial.